FCRL5 and AL amyloidosis: DFRF4539A has demonstrated efficacy in nonclinical xenograft models of human FcRH5-positive multiple myeloma8, and based on this data and an acceptable nonclinical safety profile, we tested this agent in patients with relapsed/refractory multiple myeloma in a phase I clinical trial.